Gilead Sciences has entered into a 12-year partnership with Assembly Biosciences, a biotechnology company developing antiviral therapeutics targeting serious viral diseases. The partnership, announced 17 October, aims to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D […]
Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has closed an additional US$10 million of its Series A financing, bringing the total raised to $46 million in this round. The funding will support further advancement of Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical […]
Yamaha Motor Co., Ltd. has established Tuning Fork Bio Inc. in Delaware, USA, which will analyze the antibodies in blood to better visualize people’s health conditions through its antibody profiling business. The main target markets for this new company are the U.S. and Japan.
In a deal potentially worth up to US$22 billion, Merck (known as MSD outside of the United States and Canada) has entered into a collaboration agreement with Japan-based Daiichi Sankyo to co-develop and co-commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).
Clinical Trial Application filed for combined drug targeting amyloid deposits associated with Alzheimer’s Disease.
Fapon, a leading life-science organization, signed a strategic cooperation agreement with Halodoc, the largest telehealth platform in Indonesia. This partnership brings together Fapon’s expertise in in-vitro diagnostics (IVD) technologies and integrated solutions with Halodoc’s strong sales channels and local service provisions. The partnership aims to enhance the healthcare standards in Indonesia, benefit local communities, and […]
Type 2 diabetes (T2D) is a chronic metabolic disorder that affects more than 500 million people worldwide. It is characterized by insulin resistance, a condition where the cells of the body fail to respond to insulin, resulting in hyperglycaemia.
Scientists at .NeuroRestore, Switzerland, report in the 22 September 2023 issue of Science [1] that they have developed a gene therapy that was proven in mice to stimulate nerve regrowth across spinal cord injuries and guide nerves to reconnect to their natural targets to restore mobility.
Becoming a full-fledged organism out of a handful of cells, complete with functioning tissues and organs, is a messy yet highly synchronized process that requires cells to organize themselves in a precise manner and begin working together.
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has updated its flagship platform, Cyto-Mine, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA. By meeting these requirements, the company now provides a solution to increase efficiency and productivity of cell […]
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.